Assume positive intent

About patients, about prescribers, about pharmacists, and about the agencies enforcing the rules. Almost every actor in this history was doing what their information and incentives told them to. A program that starts by identifying a villain will design instruments to catch them, and those instruments will mostly catch other people. See counting without context.

Break the cycle of shame

The single most consistent thing patients in this population report is being judged — and the consequence is that they stop telling clinicians the truth. Every clinical component of this program depends on honest answers. Shame is therefore not only cruel here; it is the mechanism by which the program would fail.

Feedback and education rather than optics

It is possible to build something that produces reassuring reports and changes nothing. The test we try to apply: does this component change a decision somebody makes? If nothing changes when a measurement changes, the measurement should not be collected. That rule is applied explicitly on remote patient monitoring and in data governance.

Publish the weak evidence

Where the evidence for a component is thin, absent or contested, it goes on the site — at the same prominence as the rest. What is not established is a page, not a footnote, and it includes figures from our own founding material that we corrected.

Can a patient refuse part of the program and keep their treatment?

Declining biometric enrollment, a site visit, monitoring or screening does not remove anyone from care and does not reduce anyone’s treatment. A consent that cannot be refused is not a consent, and a program that punishes refusal has become the thing it was built to prevent.

Will IntellaRx tell an agency whether HIPAA applies to it?

Whether HIPAA, 42 CFR Part 2, state confidentiality law, corrections rules or public records law apply to a given arrangement is a legal determination about that organization. It varies, it is consequential, and it is not ours to make. We describe what the program does in enough detail for counsel to decide. See data governance.

Identify outliers instead of marginalizing them

A patient whose dose does not match the arithmetic is a person to be understood, not a number to be corrected. This is the whole content of metabolic determination, and it generalizes.

Frequently asked questions

Why does shame matter in opioid care?

Patients in this population report being judged more consistently than anything else, and people who feel judged stop telling clinicians the truth. Every clinical part of this program depends on honest answers. So shame is not only cruel here; it is the exact mechanism by which the program would fail. Breaking that cycle is a working requirement, not a slogan.

Does IntellaRx collect data it does not use?

No. The test is simple: does this component change a decision somebody makes? If nothing changes when a measurement changes, that measurement should not be collected. The rule is applied explicitly to remote patient monitoring and in data governance, so reassuring reports that change nothing do not get built.

Are patients on high opioid doses treated as suspects?

No. The program assumes positive intent about patients, prescribers, pharmacists and agencies alike. A patient whose dose does not match the arithmetic is a person to be understood, not a number to be corrected. That idea is the whole content of metabolic determination, and it applies across the program.